NCT05004987 - Aβ Dynamics in LLMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

January 29, 2027

Conditions

Alzheimer DiseaseMajor Depressive Disorder

Interventions

DRUG

Escitalopram Oxalate

The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.

DRUG

Placebo

Daily dose of placebo will mimic that of ESC.

Trial Locations (2)

10016

RECRUITING

NYU Langone Health, New York

10962

RECRUITING

Nathan S. Kline Institute for Psychiatric Research, Orangeburg

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

NYU Langone Health

OTHER